GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Embla Medical hf (OTCPK:OSSFF) » Definitions » 5-Year RORE %

OSSFF (Embla Medical hf) 5-Year RORE % : 21.47% (As of Sep. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Embla Medical hf 5-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Embla Medical hf's 5-Year RORE % for the quarter that ended in Sep. 2024 was 21.47%.

The industry rank for Embla Medical hf's 5-Year RORE % or its related term are showing as below:

OSSFF's 5-Year RORE % is ranked better than
79.14% of 671 companies
in the Medical Devices & Instruments industry
Industry Median: -4.02 vs OSSFF: 21.47

Embla Medical hf 5-Year RORE % Historical Data

The historical data trend for Embla Medical hf's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Embla Medical hf 5-Year RORE % Chart

Embla Medical hf Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
5-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.87 -18.01 3.77 -15.22 -2.85

Embla Medical hf Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.19 -2.85 -0.75 18.94 21.47

Competitive Comparison of Embla Medical hf's 5-Year RORE %

For the Medical Devices subindustry, Embla Medical hf's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Embla Medical hf's 5-Year RORE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Embla Medical hf's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where Embla Medical hf's 5-Year RORE % falls into.



Embla Medical hf 5-Year RORE % Calculation

Embla Medical hf's 5-Year RORE % for the quarter that ended in Sep. 2024 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( 0.162-0.045 )/( 0.567-0.022 )
=0.117/0.545
=21.47 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2024 and 5-year before.


Embla Medical hf  (OTCPK:OSSFF) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Embla Medical hf 5-Year RORE % Related Terms

Thank you for viewing the detailed overview of Embla Medical hf's 5-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Embla Medical hf Business Description

Traded in Other Exchanges
Address
Grjothals 5, Reykjavik, ISL
Embla Medical hf is a provider of prosthetics and bracing and supports solutions; FIOR & GENTZ, an innovative developer of neuro orthotics; and College Park, creators of custom-built prosthetic solutions for people of all activity levels..

Embla Medical hf Headlines

From GuruFocus

Q3 2019 Ossur hf Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q1 2021 Ossur hf Earnings Call Transcript

By GuruFocus Research 02-14-2024

Embla Medical hf: Interim Report Q2 2024

By PRNewswire 07-23-2024

Q3 2022 Ossur hf Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q2 2020 Ossur hf Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q1 2024 Embla Medical hf Earnings Call Transcript

By GuruFocus Research 04-24-2024

Q4 2023 Ossur hf Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q4 2022 Ossur hf Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q3 2021 Ossur hf Earnings Call Transcript

By GuruFocus Research 02-14-2024